Cargando…

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro

Background. Resistance to radiation therapy poses a major clinical problem for patients suffering from head and neck squamous cell carcinoma (HNSCC). Transforming growth factor ß (TGF-ß) has emerged as a potential target. This study aimed to investigate the radiosensitizing effect of galunisertib, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jank, Bernhard J., Lenz, Teresa, Haas, Markus, Kadletz-Wanke, Lorenz, Campion, Nicholas J., Schnoell, Julia, Heiduschka, Gregor, Macfelda, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098568/ https://www.ncbi.nlm.nih.gov/pubmed/34985593 http://dx.doi.org/10.1007/s10637-021-01207-1

Ejemplares similares

The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines
por: Haas, Markus, et al.
Publicado: (2022)

Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma
por: Schnoell, Julia, et al.
Publicado: (2021)

µ-Crystallin Is Associated with Disease Outcome in Head and Neck Squamous Cell Carcinoma
por: Jank, Bernhard J., et al.
Publicado: (2021)

The prognostic role of PSMD14 in head and neck squamous cell carcinoma
por: Schnoell, Julia, et al.
Publicado: (2022)

The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
por: Schnoell, Julia, et al.
Publicado: (2023)

High USP4 mRNA is associated with an HPV-positive status in head and neck squamous cell carcinoma patients
por: Scheiflinger, Alexandra, et al.
Publicado: (2023)

Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck
por: Schnoell, Julia, et al.
Publicado: (2022)

Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
por: Schnoell, Julia, et al.
Publicado: (2020)

The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer
por: Haas, Markus, et al.
Publicado: (2023)

Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab
por: Haas, Markus, et al.
Publicado: (2023)

Prognostic Relevance of Thyroid-Hormone-Associated Proteins in Adenoid Cystic Carcinoma of the Head and Neck
por: Schnoell, Julia, et al.
Publicado: (2021)

Analysis of Perioperative Platelet Indices and Their Prognostic Value in Head and Neck Cancer Patients Treated with Surgery and Postoperative Radiotherapy: A Retrospective Cohort Study
por: Jank, Bernhard J., et al.
Publicado: (2019)

β-CATENIN is a positive prognostic marker for HPV-positive head and neck squamous cell carcinoma
por: Stoiber, Stefan, et al.
Publicado: (2023)

Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma
por: Kotowski, Ulana, et al.
Publicado: (2019)

Inhibition of beta-catenin shows therapeutic potential in head and neck squamous cell carcinoma in vitro
por: Maier, Tobias, et al.
Publicado: (2022)

Expression of inhibitors of apoptosis proteins in salivary gland adenoid cystic carcinoma: XIAP is an independent marker of impaired cause‐specific survival
por: Schnoell, Julia, et al.
Publicado: (2020)

Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma
por: Brkic, Faris F., et al.
Publicado: (2022)

Targeting Wnt/Beta-Catenin Signaling in HPV-Positive Head and Neck Squamous Cell Carcinoma
por: Brkic, Faris F., et al.
Publicado: (2022)

The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
por: Brkic, Faris F., et al.
Publicado: (2021)

Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer
por: Spielvogel, Clemens P., et al.
Publicado: (2022)

AF1q Expression Associates with CD44 and STAT3 and Impairs Overall Survival in Adenoid Cystic Carcinoma of the Head and Neck
por: Kadletz, Lorenz C., et al.
Publicado: (2019)

In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma
por: Varatanovic, Sara, et al.
Publicado: (2023)

Evaluation of the External Jugular Vein Overlying the Sternocleidomastoid Muscle as Venous Lymph-Node Flap
por: Kadletz-Wanke, Lorenz, et al.
Publicado: (2022)

Potential association of the prognostic index and survival in patients with p16-positive oropharyngeal squamous cell carcinoma
por: Brkic, Faris F., et al.
Publicado: (2021)

Correction to: Potential association of the prognostic index and survival in patients with p16-positive oropharyngeal squamous cell carcinoma
por: Brkic, Faris F., et al.
Publicado: (2021)

In vitro antineoplastic effects of MK0752 in HPV-positive head and neck squamous cell carcinoma
por: Varatanovic, Sara, et al.
Publicado: (2023)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
por: Friedl, Marlene, et al.
Publicado: (2022)

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2020)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Cardiomyocyte SMAD4-Dependent TGF-β Signaling is Essential to Maintain Adult Heart Homeostasis
por: Umbarkar, Prachi, et al.
Publicado: (2019)

The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells
por: Nicolai, Alice, et al.
Publicado: (2022)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
por: Zhang, Chao, et al.
Publicado: (2016)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s6mtjp7bhd19r46d26ou2b7slh